Summary. Exacerbations of COPD are common and can be detrimental to both patient health and health care costs. Corticosteroids are recommended by consensus guidelines for patients during ...
Loneliness is a key risk factor for symptom exacerbations and hospitalizations in people with COPD, highlighting the need for ...
Only 18% of eligible acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients participated in post-discharge pulmonary rehabilitation (PR), with significant ineligibility ...
Discover how moderate-to-vigorous physical activity can reduce exacerbations and corticosteroid use in COPD patients on dual ...
A 68-year old critically-ill patient from Lakshadweep, diagnosed with acute chronic obstructive pulmonary disease and a respiratory failure, was evacuated in an aircraft by the Indian Coast Guard and ...
There are many myths and misconceptions about COPD — such as only those who smoke can get it. Knowing the realities of the condition can help you separate fact from fiction. Chronic obstructive ...
The following is a summary of “Investigation of the Relationship Between the Measured Alpha Angle in Capnography and Readmission Within Thirty Days in Chronic Obstructive Pulmonary Disease Patients ...
Dupilumab in COPD was associated with decreased risk of mortality, emergency visits, exacerbations, and respiratory failure and infections.
A new study reveals that ensifentrine, a novel COPD treatment, significantly reduces COPD-related healthcare usage over 48 ...
Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of chronic obstructive pulmonary disease (AECOPD) participated in post ...
Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.
2010;67(13):1061-1069. Considering all of the data and their limitations, questions still remain regarding the optimal treatment of COPD exacerbations. The data of deJong et al. [30] showed no ...